Impact of baseline, trend, and normalization of carcinoembryonic antigen on survival in epidermal growth factor receptor-mutant non-small cell lung cancer patients treated with first-line epidermal growth factor receptor tyrosine kinase inhibitors

被引：0
|
作者：
Chen, Y. -M. [1 ]
Lai, C. -H. [1 ]
Lin, M. -C. [1 ]
机构：
[1] Kaohsiung Chang Gung Mem Hosp, Internal Med, Kaohsiung, Taiwan
来源：
ANNALS OF ONCOLOGY | 2015年 / 26卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
450P
引用
收藏
页码：138 / 138
页数：1
相关论文
共 50 条
  • [1] Baseline, Trend, and Normalization of Carcinoembryonic Antigen as Prognostic Factors in Epidermal Growth Factor Receptor-Mutant Nonsmall Cell Lung Cancer Patients Treated With First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
    Chen, Yu-Mu
    Lai, Chien-Hao
    Chang, Huang-Chih
    Chao, Tung-Ying
    Tseng, Chia-Cheng
    Fang, Wen-Feng
    Wang, Chin-Chou
    Chung, Yu-Hsiu
    Huang, Kuo-Tung
    Chen, Hung-Cheng
    Chang, Ya-Chun
    Lin, Meng-Chih
    MEDICINE, 2015, 94 (50)
  • [2] Baseline and Trend of Lymphocyte-to-Monocyte Ratio as Prognostic Factors in Epidermal Growth Factor Receptor Mutant Non-Small Cell Lung Cancer Patients Treated with First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
    Chen, Yu-Mu
    Lai, Chien-Hao
    Chang, Huang-Chih
    Chao, Tung-Ying
    Tseng, Chia-Cheng
    Fang, Wen-Feng
    Wang, Chin-Chou
    Chung, Yu-Hsiu
    Wang, Yi-Hsi
    Su, Mao-Chang
    Huang, Kuo-Tung
    Chen, Hung-Chen
    Chang, Ya-Chun
    Lin, Meng-Chih
    PLOS ONE, 2015, 10 (08):
  • [3] Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in the Treatment of Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Metastatic to the Brain
    Jamal-Hanjani, Mariam
    Spicer, James
    CLINICAL CANCER RESEARCH, 2012, 18 (04) : 938 - 944
  • [4] Impact of clinical parameters and systemic inflammatory status on epidermal growth factor receptor-mutant non-small cell lung cancer patients readministration with epidermal growth factor receptor tyrosine kinase inhibitors
    Chen, Yu-Mu
    Lai, Chien-Hao
    Rau, Kun-Ming
    Huang, Cheng-Hua
    Chang, Huang-Chih
    Chao, Tung-Ying
    Tseng, Chia-Cheng
    Fang, Wen-Feng
    Chung, Yu-Hsiu
    Wang, Yi-Hsi
    Su, Mao-Chang
    Huang, Kuo-Tung
    Liu, Shih-Feng
    Chen, Hung-Chen
    Chang, Ya-Chun
    Chang, Yu-Ping
    Wang, Chin-Chou
    Lin, Meng-Chih
    BMC CANCER, 2016, 16
  • [5] Impact of clinical parameters and systemic inflammatory status on epidermal growth factor receptor-mutant non-small cell lung cancer patients readministration with epidermal growth factor receptor tyrosine kinase inhibitors
    Yu-Mu Chen
    Chien-Hao Lai
    Kun-Ming Rau
    Cheng-Hua Huang
    Huang-Chih Chang
    Tung-Ying Chao
    Chia-Cheng Tseng
    Wen-Feng Fang
    Yu-Hsiu Chung
    Yi-Hsi Wang
    Mao-Chang Su
    Kuo-Tung Huang
    Shih-Feng Liu
    Hung-Chen Chen
    Ya-Chun Chang
    Yu-Ping Chang
    Chin-Chou Wang
    Meng-Chih Lin
    BMC Cancer, 16
  • [6] Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer
    Tan, Chee-Seng
    Cho, Byoung-Chul
    Soo, Ross A.
    LUNG CANCER, 2016, 93 : 59 - 68
  • [7] Antacid Use and De Novo Brain Metastases in Patients with Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Who Were Treated Using First-Line First-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
    Chen, Yu-Mu
    Lai, Chien-Hao
    Chang, Huang-Chih
    Chao, Tung-Ying
    Tseng, Chia-Cheng
    Fang, Wen-Feng
    Wang, Chin-Chou
    Chung, Yu-Hsiu
    Wang, Yi-Hsi
    Su, Mao-Chang
    Liu, Shih-Feng
    Huang, Kuo-Tung
    Chen, Hung-Chen
    Chang, Ya-Chun
    Lin, Meng-Chih
    PLOS ONE, 2016, 11 (02):
  • [8] Is there a role for epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor wildtype non-small cell lung cancer?
    Arriola, Edurne
    Taus, Alvaro
    Casadevall, David
    WORLD JOURNAL OF CLINICAL ONCOLOGY, 2015, 6 (04): : 45 - 56
  • [9] Epidermal growth factor receptor-mutant non-small cell lung Cancer and Choroidal metastases: long-term outcome and response to epidermal growth factor receptor tyrosine kinase inhibitors
    Bouchez, Clementine
    Pluvy, Johan
    Soussi, Ghassen
    Nguenang, Marina
    Brosseau, Solenn
    Tourne, Morgan
    Collin, Megane
    Theou-Anton, Nathalie
    Guyard, Alice
    Ammar, Jamila
    Khalil, Antoine
    Zalcman, Gerard
    Gounant, Valerie
    BMC CANCER, 2020, 20 (01)
  • [10] Neutrophil to Lymphocyte Ratio as a Prognostic Factor in European Patients with Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Treated with Tyrosine Kinase Inhibitors
    Aguiar-Bujanda, David
    Duenas-Comino, Arancha
    Saura-Grau, Salvador
    Ros-Sanjuan, Laura
    Blanco-Sanchez, Maria J.
    Hernandez-Sosa, Maria
    Mori-De Santiago, Marta
    Galvan-Ruiz, Saray
    Lorenzo-Barreto, Jose E.
    Vargas-Prado, Ana M.
    Bohn-Sarmiento, Uriel
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 (12) : 755 - 760
12345